Expert Opin Pharmacother. 2003 Apr; 4(4): 433-43.

New developments in migraine prophylaxis.

Bigal ME, Krymchantowski AV, Rapoport AM.

Department of Neurology, Albert Einstein College of Medicine, New York, USA. mbigal@aecom.yu.edu

Migraine is a common neurological disorder that afflicts > or = 12% of the adult US population. Severe, frequent and disabling attacks require effective prophylaxis. Traditional preventive drugs such as beta-blockers, antidepressants and calcium antagonists, despite their documented efficacy, fail to offer relief for a significant proportion of migraine sufferers. Multiple threads of research over the last 15 years have led to the concept that migraine is generated from a hyperexcitable brain. This opens new perspectives in terms of preventive options, especially regarding the anticonvulsants agents. Additionally, different groups of substances, some of which nominated as non-orthodox agents, have been recently subjected to clinical trials and found to be effective. The aim of this review is to present and discuss the new options for migraine prevention.